The company succeeded artificial culture of Ceriporia lacerata for food and medicine for the first time in the world, and thereby successfully materialized the innovative new material ‘CLEPS’

Ceriporia lacerata

is a species of white-rot fungi that is sacrophytic, living on oak or pine trees, and it is an organism that contain active ingredients such as extracellular polysaccharide(EPS) and β-glucan. It was first discovered in 2002 in Japan and reported to the academic world, And now Fugenbio is promiting world’s first commercialization of Ceriporia lacerata for food and drug.

What is CLEPS?

CLEPS is the key functional ingredients prpoduced by Ceriporia lacerata mycelium, which is formed by secretion of polysaccharide into the extracellular region, i.e. around the cells or culture medium. It is produced when mycelium absorbs carbohydrates and proteins to protect itself from the oxygen-poor aquatic environment and to strengthen the metabolic capability.
Through various studies, Fugenbio has confirmed that CLEPS is a pharmaceutical component effective for prevention or treatment of diverse indications, for example, control of blood sugar and blood pressure, and improvement of liver and immune function, etc.

CLEPS Biosynthesis Process

The company established the optimal liquid culture medium and culture conditions for CLEPS synthesis and achieved commercialization.


Providing optimal nutritive components and creating the best environment for production of Ceriporia mycelium and CLEPS


Biosynthesizing the new substance, CLEPS, in order to increase vitality of the cells in an environment deficient in nutrient and oxygen


Secretion of CLEPS to the outside in order for the mycelium under stress to protect itself